PubMed · 16897841
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Mark Nicholls. 2006-08-08. Viewpoint: ICD cost-effectiveness.. https://pubmed.ncbi.nlm.nih.gov/16897841/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Patients with implanted cardiac devices and their physicians may defer important electrodiagnostic testing because of anxiety about potential negative effects on the device. To determine the safety of routine nerve conduction studies (NCS) in this population, 10 patients with permanent dual-chamber pacemakers of various types and five patients with implanted cardiac defibrillators (ICD) underwent nerve stimulation at sites commonly used during NCS. The implanted cardiac device was interrogated before and after the study and there was continuous monitoring of the surface electrocardiogram (ECG) and atrial and ventricular electrograms. Electrical impulses generated during routine NCS were never detected by the sensing amplifier and did not affect the programmed settings of the implanted cardiac device. We conclude that routine NCS is safe in patients with implanted cardiac pacemakers with bipolar sensing configurations and defibrillators.
PURPOSE OF REVIEW: Clinical trial evidence suggests that traditional right ventricular apical pacing may be harmful. This review summarizes the existing evidence and outlines the major avenues of ongoing research in this field. RECENT FINDINGS: Despite theoretical advantages of dual-chamber pacing, large randomized trials found only a small advantage over single-chamber ventricular pacing. Subsequent analysis of one of these trials suggested that this was due to the tendency for dual-chamber pacemakers to produce frequent, unnecessary right ventricular pacing. This hypothesis is supported by a prospective study among defibrillator recipients, showing that dual-chamber pacing results in a very high frequency of ventricular pacing and worse clinical outcomes, compared with backup ventricular pacing. These observations have led to a renewed interest in single-chamber atrial pacing for sinus node dysfunction, the development of new dual-chamber pacemaker algorithms designed to minimize right ventricular pacing, and the search for better ways to pace the ventricles in patients who require ventricular pacing. SUMMARY: Conventional right ventricular apical pacing should be avoided whenever possible. In patients who require ventricular pacing, ongoing research will determine if selected-site pacing or multisite pacing improves clinical outcomes compared with traditional right ventricular apical pacing.
PURPOSE OF REVIEW: Sudden cardiac death remains a major cause of mortality among patients with cardiomyopathy and implantable cardioverter-defibrillator therapy has been shown to improve survival in these patients. Effective use of prophylactic implantable cardioverter-defibrillator therapy requires accurate risk stratification beyond assessment of ejection fraction, however. Repolarization alternans is a harbinger of ventricular arrhythmias and its measurement from body-surface recordings, also known as microvolt T-wave alternans, is emerging as an effective prognostic tool in these patients based on recent clinical trials. RECENT FINDINGS: We review the pathogenesis and determinants of repolarization alternans. The current techniques for measuring T-wave alternans from the body surface are compared, including the spectral and modified moving average methods. Recent clinical trials evaluating the prognostic utility of T-wave alternans in patients with ischemic and nonischemic cardiomyopathy and no prior arrhythmic events are summarized. The findings of these studies are discussed in the context of implantable cardioverter-defibrillator prophylaxis. Body-surface T-wave alternans is an evolving technique and its limitations are presented along with approaches to improve its predictive accuracy. SUMMARY: Risk stratification with T-wave alternans has the potential to guide prophylactic implantable cardioverter-defibrillator therapy in a growing population of patients with cardiomyopathy.